| |
Patient
|
Gender
|
Age
|
Clinical stage
|
AC [cm]
|
Chemotherapy
|
CEA
|
CA 19-9
|
Type of surgery
|
Histology
|
Grade
|
L/V/P
|
cT
|
cN
|
ypT
|
ypN
|
TRG
|
Residual cancer cells Avg/Max %
|
Local relaps
|
Distant relaps
|
|---|
|
Responders
|
01
|
M
|
30
|
IIIA
|
12
|
Xel
|
N
|
N
|
LAR
|
A
|
1
|
0
|
1
|
1
|
1
|
0
|
2
|
1/5
|
0
|
0
|
|
02
|
F
|
62
|
IIIA
|
13
|
Xel
|
N
|
N
|
LAR
|
A
|
2
|
0
|
x
|
1
|
1
|
1
|
2
|
2,5/5
|
0
|
0
|
|
03
|
F
|
67
|
IIA
|
3,5
|
Xel
|
N
|
N
|
APR
|
A
|
2
|
0
|
3
|
0
|
1
|
0
|
2
|
7,5/15
|
0
|
0
|
|
04
|
M
|
43
|
IIIA
|
9
|
Xel
|
N
|
N
|
uLAR
|
A
|
1
|
0
|
2
|
1
|
0
|
0
|
1
|
0/0
|
0
|
0
|
|
05
|
M
|
40
|
IIIB
|
5
|
Xel
|
E
|
N
|
APR
|
A
|
2
|
0
|
3
|
1
|
3
|
1
|
2
|
1/5
|
0
|
0
|
|
06
|
M
|
73
|
IIA
|
6,5
|
Xel
|
N
|
E
|
uLAR
|
A
|
2
|
0
|
3
|
0
|
0
|
0
|
1
|
0/0
|
0
|
0
|
|
07
|
M
|
68
|
IIIC
|
6
|
Xel
|
E
|
E
|
APR
|
A
|
2
|
0
|
3
|
2
|
0
|
0
|
1
|
0/0
|
0
|
0
|
|
08
|
M
|
58
|
IIIB
|
13
|
Xel
|
N
|
N
|
APR
|
A
|
1
|
0
|
3
|
1
|
3
|
0
|
2
|
2,5/40
|
0
|
Y
|
|
09
|
M
|
68
|
IIA
|
4,5
|
5FU
|
N
|
N
|
APR
|
A
|
2
|
0
|
3
|
0
|
0
|
0
|
1
|
0/0
|
0
|
0
|
|
10
|
M
|
43
|
IIA
|
4
|
Xel
|
N
|
N
|
uLAR
|
MA
|
2
|
0
|
3
|
0
|
0
|
0
|
1
|
0/0
|
0
|
0
|
|
Non-responders
|
11
|
M
|
63
|
IIIB
|
7
|
Xel
|
E
|
N
|
uLAR
|
A
|
2
|
0
|
3
|
1
|
2
|
0
|
4
|
15/50
|
0
|
0
|
|
12
|
M
|
59
|
IIIB
|
9
|
Xel
|
E
|
N
|
LAR
|
A
|
2
|
0
|
3
|
1
|
3
|
0
|
4
|
40/60
|
0
|
0
|
|
13
|
M
|
45
|
IIIC
|
4
|
Xel
|
N
|
N
|
APR
|
A
|
2
|
1P
|
3
|
2
|
3
|
1
|
3
|
7,5/50
|
Y
|
Y
|
|
14
|
F
|
64
|
IIIC
|
11
|
Xel
|
N
|
N
|
LAR
|
A
|
2
|
0
|
3
|
2
|
2
|
0
|
4
|
50/70
|
0
|
0
|
|
15
|
F
|
60
|
IIIA
|
9
|
Xel
|
N
|
N
|
LAR
|
A
|
1
|
0
|
2
|
1
|
1
|
0
|
4
|
70/80
|
0
|
0
|
|
16
|
F
|
69
|
IIIC
|
8
|
Xel
|
N
|
N
|
LAR
|
A
|
1
|
0
|
3
|
2
|
3
|
1
|
4
|
25/70
|
0
|
0
|
|
17
|
M
|
32
|
IIIC
|
10
|
Xel
|
N
|
N
|
LAR
|
A
|
2
|
0
|
2
|
2
|
3
|
0
|
4
|
55/75
|
0
|
0
|
|
18
|
M
|
53
|
IIIC
|
4
|
Xel
|
N
|
N
|
APR
|
A
|
3
|
0
|
3
|
2
|
2
|
0
|
3
|
40/60
|
0
|
0
|
|
19
|
M
|
63
|
IV*
|
7
|
5FU
|
E
|
N
|
APR
|
MA
|
2
|
0
|
3
|
2
|
3
|
2
|
4
|
60/80
|
0
|
Y
|
|
20
|
F
|
52
|
IIA
|
8
|
Xel
|
N
|
N
|
LAR
|
A
|
2
|
0
|
3
|
0
|
2
|
1
|
3
|
60/70
|
0
|
0
|
- N – Normal; E – Elevated; LAR – Low Anterior Resection; uLAR – Ultra (extended) Low Anterior Resection; APR –Abdominoperineal Resection; A – Adenocarcinoma; MA – Mucinous Adenocarcinoma; L/V/P – Lymphatic/Vascular/Perineural Invasion; 1P – Positive Perineural Invasion; TRG – Tumor Regression Score according to Mandard et al. (10); CEA – Carcinoembryonic antigen; CA 19–9 – cancer antigen 19–9; Clinical stage – according to TNM /UICC cancer staging classification, 6th Edition (ref. 5); cT/cN – clinical staging of primary tumor (T) / regional lymphatic nodes (N); ypT/ypN – histopathological staging of primary tumor and regional lymphatic nodes after neoadjuvant treatment; Residual cancer cells (Avg/Max %) – a proportion of cancer cells in all paraffin embedded tisue slices of primary tumor histologicaly examined after neoadjuvant treatment: Average (%) / Maximum (%) of cancer cells presented in examined slices; Xel – Xeloda (capecitabine); 5FU – 5-fluorouracil; M – male; F – female; AC – distance between the anocutaneous line and distal (aboral) margin of the tumor in cm; Y – yes; * in such patient a radical metastasectomy of solitary liver metastasis was first performed, followed by neoadjuvantchemoradiotherapy for locally advanced rectal cancer.
